Mesoblast posts 44% revenue rise as RYONCIL demand accelerates
Mesoblast Limited has reported a 44% year-on-year increase in net revenues for its first fiscal quarter ended 30 September 2026, driven by continued commercial uptake of RYONCIL (remestemcel-L-rknd) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in paediatric patients. The dual-listed company, which trades on both Nasdaq and the ASX, held US$99 million in cash at the end of the quarter and reduced its operating cash spend by 86% to US$2.1 million, compared with US$14.9 million in the prior year period.
RYONCIL net revenue for the quarter reached US$28 million. Mesoblast noted that September recorded the highest number of new patient starts in the period, partly reflecting a recovery in treatment scheduling following the summer recess slowdown typical in July and August. The company is also enrolling patients in a registration trial for RYONCIL in adult SR-aGvHD, with up to 40 US sites expected to be activated by year end, representing roughly 60% of the approximately 8,500 annual allogeneic adult bone marrow transplants performed in the country.
Pipeline progress: chronic pain and heart failure
Beyond its commercial product, Mesoblast completed treatment of all enrolled patients in its expanded 350-patient Phase 3 pivotal trial of rexlemestrocel-L for chronic inflammatory low back pain due to degenerative disc disease. The trial's primary endpoint is 12-month durable pain reduction, with results expected to read out next year.
On the cardiovascular front, Mesoblast met with the FDA and received confirmation that a Biologics License Application for rexlemestrocel-L may proceed for patients with end-stage heart failure with reduced ejection fraction who are dependent on a left ventricular assist device and who suffer life-threatening major gastrointestinal bleeding. The candidate holds both Regenerative Medicine Advanced Therapy and Orphan Drug designations for this indication. Formal minutes of the FDA meeting are expected shortly.
Chief executive Silviu Itescu said the quarter demonstrated "substantial improvement in our net operating cash spend while continuing to advance our strategic objectives for rexlemestrocel-L in chronic pain and cardiovascular diseases."
Market context and competitive landscape
RYONCIL remains the only FDA-approved mesenchymal stromal cell therapy, a distinction that affords Mesoblast a degree of commercial insulation in the near term. The broader allogeneic cell therapy space, however, is advancing rapidly: a number of academic spinouts and well-capitalised biotechs are pursuing off-the-shelf cell platforms across oncology, autoimmune disease, and inflammatory indications, and competition for transplant-centre attention is intensifying.
The LVAD-associated GI bleeding indication is relatively niche, but carries significant unmet need and the RMAT designation provides a structured FDA engagement pathway that could compress development timelines. Investors will focus on the Phase 3 CLBP readout next year as the next material value inflection, given that a prior rexlemestrocel-L programme in that indication faced setbacks at the agency level. The improved cash position and sharply reduced operating burn give the company meaningful runway to reach those milestones without an immediate requirement for dilutive financing.